vimarsana.com
Home
Live Updates
Higher Relapse Rate With Rituximab vs Ocrelizumab in MS Registry Data : vimarsana.com
Higher Relapse Rate With Rituximab vs Ocrelizumab in MS Registry Data
Rituximab did not show non-inferiority in comparative effectiveness study
Related Keywords
Denmark
,
Danish
,
Judy George
,
Rituximab Rituxan
,
Research In Multiple Sclerosis
,
European Committee For Treatment
,
Danish Multiple Sclerosis Registry
,
Expanded Disability Status Scale
,
Medpage Today
,
vimarsana.com © 2020. All Rights Reserved.